Tag Archives: Mirati Therapeutics

Mirati Therapeutics (MRTX) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Edward White maintained a Buy rating on Mirati Therapeutics (MRTX – Research Report) today and set a price target of $117. The company’s shares closed yesterday at $93.65. White observed: “Our $117 price target is based on

Mirati Therapeutics (MRTX) Gets a Buy Rating from Cowen & Co.

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Mirati Therapeutics (MRTX – Research Report) yesterday. The company’s shares closed yesterday at $93.65. According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 5.2% and

JonesTrading Believes Mirati Therapeutics (NASDAQ: MRTX) Still Has Room to Grow

JonesTrading analyst Soumit Roy reiterated a Buy rating on Mirati Therapeutics (MRTX – Research Report) today. The company’s shares closed yesterday at $99, close to its 52-week high of $109.64. Roy commented: “Amgen’s (AMGN, Not Rated) 2Q earnings updates provided

Cowen & Co. Believes Mirati Therapeutics (NASDAQ: MRTX) Won’t Stop Here

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Mirati Therapeutics (MRTX – Research Report) today. The company’s shares closed yesterday at $89.20, close to its 52-week high of $96.70. According to TipRanks.com, Shibutani is a 3-star analyst

Analysts Offer Insights on Healthcare Companies: Mirati Therapeutics (NASDAQ: MRTX) and Spectrum Pharmaceuticals (NASDAQ: SPPI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mirati Therapeutics (MRTX – Research Report) and Spectrum Pharmaceuticals (SPPI – Research Report). Mirati Therapeutics (MRTX) In a report released yesterday, Varun Kumar

Cowen & Co. Reaffirms Their Buy Rating on Mirati Therapeutics (MRTX)

In a report released today, Chris Shibutani from Cowen & Co. reiterated a Buy rating on Mirati Therapeutics (MRTX – Research Report). The company’s shares closed yesterday at $67.18. According to TipRanks.com, Shibutani is a 3-star analyst with an average